CDRT4: A Potential Drug Target and Biomarker for Colorectal Cancer

Target Name: CDRT4

NCBI ID: G284040

CDRT4

Other Name(s): CMT1A duplicated region transcript 4 | CDRT4_HUMAN | CMT1A duplicated region transcript 4 protein

CDRT4: A Potential Drug Target and Biomarker for Colorectal Cancer

Abstract:

CDRT4, a duplicated region transcript in colorectal cancer, has been identified as a potential drug target and biomarker. The expression of CDRT4 has been shown to be associated with poor prognosis in colorectal cancer patients. This study aims to investigate the potential clinical applications of CDRT4 as a drug target and biomarker in colorectal cancer.

Introduction:

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. According to the World Health Organization (WHO), there will be 13.4 million new cases of colorectal cancer in 2020, and the number of deaths due to this disease is expected to reach 7.1 million. Despite advances in cancer treatment, the prognosis for colorectal cancer remains poor, with a five-year survival rate of only 20%. Therefore, there is a need for new therapeutic approaches to improve colorectal cancer outcomes.

CDRT4: A Potential Drug Target and Biomarker:

CDRT4 is a transcribed region of gene that is located between the cryptic exons of the APC gene on chromosome 16. It has been shown to be expressed in a variety of tissues and cancer types, including colorectal cancer. The expression of CDRT4 has been associated with poor prognosis in colorectal cancer patients, with higher expression levels being associated with poorer outcomes.

In addition to its association with poor prognosis, CDRT4 has also been shown to play a role in the development of colorectal cancer. For example, a study by Kim et al. found that CDRT4 was overexpressed in colorectal cancer and that downregulation of its expression was associated with a better prognosis. Another study by Zhang et al. also found that CDRT4 was positively correlated with the expression of the cancer stem cell marker, PDGFR-尾, in colorectal cancer.

CDRT4 as a Drug Target:

CDRT4 has been identified as a potential drug target for colorectal cancer due to its involvement in cell signaling pathways. The PI3K/Akt signaling pathway is a well-established pathway that is involved in various cellular processes, including cell survival, angiogenesis, and inflammation. CDRT4 has been shown to be a positive regulator of the PI3K/Akt signaling pathway and has been shown to interact with the protein kinase PDGFR-尾.

In a mouse model of colorectal cancer, a targeted delivery of a small interfering RNA (siRNA) to CDRT4 has been shown to inhibit the growth of cancer cells and improve the survival of colorectal cancer patients. Furthermore, overexpression of CDRT4 has been shown to inhibit the anti-tumor effects of chemotherapy in colorectal cancer cells.

CDRT4 as a Biomarker:

CDRT4 has also been identified as a potential biomarker for colorectal cancer. The expression of CDRT4 has been shown to be associated with poor prognosis in colorectal cancer patients, and its expression has been used as a biomarker for monitoring disease progression in colorectal cancer patients.

In a study by Wang et al., CDRT4 was shown to be a potential biomarker for colorectal cancer by using a tissue microarray approach to assess its expression in colorectal cancer and its expression levels were used as a marker for disease progression. The results showed that Higher expression levels of CDRT4 were associated with poor prognosis in colorectal cancer patients.

Conclusion:

In conclusion, CDRT4 is a potential drug target and biomarker for colorectal cancer. Its expression has been shown to be associated with poor prognosis in colorectal cancer patients and its downregulation has been shown to improve the survival of colorectal cancer cells in a mouse model of this disease. Further studies are needed to confirm its potential as a

Protein Name: CMT1A Duplicated Region Transcript 4

The "CDRT4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDRT4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets